Circulating levels of active transforming growth factor β1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score

Rheumatology

Volumn 44, Issue 12, 2005, Pages 1518-1524

  Dziadzio, M ^a   Smith, R E ^a   Abraham, D J ^a   Black, C M ^a   Denton, C P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Biological markers; Scleroderma; Severity of illness index; Systemic sclerosis; Transforming growth factor beta

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCLERODERMA; SCORING SYSTEM; SYSTEMIC SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 28544437285     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei088     Document Type: Article

References (38)

1. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β. Growth Factors 1993;8:1-9.
2. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-8.
3. Black CM, Denton CP. Systemic sclerosis and related disorders in adults and children. In: Maddison PG, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology, 2nd Edn, Vol. 2. Oxford: Oxford University Press, 1998:1217-47.
4. Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: Cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:506-11.
5. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor-β causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochemistry 1987;297:597-604.
6. Varga J. Antifibrotic therapy in scleroderma: Extracellularly activated fibroblasts? Curr Rheumatol Rep 2004;6:164-70.
7. Smith EA, LeRoy EC. A possible role for transforming growth factor beta in systemic sclerosis. J Invest Dermatol 1990;95:125S-127S.
8. Wahl SM, Hunt DA, Wong HL et al. Transforming growth factor β is a potent immunosuppressive that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 1988;140:3026-32.
9. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFβ activation. J Cell Sci 2003;116:217-24.
10. Taipale J, Miyazana K, Heldin CH, Keski-Oja J. Latent transforming growth factor β associates to fibroblasts extracellular matrix via latent transforming growth factor β binding protein. J Cell Biol 1994;124:171-81.
11. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Arthritis Rheum 1989;32:817-25.
12. Falanga V, Julien J. Observations in the potential role of transforming growth factor-β in cutaneous fibrosis: Systemic sclerosis. In: Piez K, Sporn M, eds. Transforming Growth Factor-betas. Chemistry, Biology and Therapeutics. New York: New York Academy of Science. 1990:161-71.
13. Keystone E, Lok C, Appleton B, Narenden N, Lee P, Paige C. Elevated serum levels of TGFβ in patients with scleroderma. Arthritis Rheum 1992;35S:206 (abstract).
14. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localisation and serologic detection of transforming growth factor beta-1. Arthritis Rheum 1994;37:278-88.
15. Snowden N, Coupes B, Herrick A, Illingworth K, Jayson MIV, Brenchley PEC. Plasma TGFβ in systemic sclerosis: A cross-sectional study. Ann Rheum Dis 1994;53:763-7.
16. Giacomelli R, Cipriani P, Danese C et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta-1. J Rheumatol 1996;23:291-6.
17. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
18. Choi J, Min D, Lacho M et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003;30:1529-33.
19. McHugh NJ, Distler O, Giacomelli R, Riemekasten G. Non organ based laboratory markers in systemic sclerosis. Clin Exp Rheumatol 2003; 21(Suppl. 29):S32-S38.
20. Valentini G, Medsger TA Jr, Silman AJ, Bombardieri S. Conclusion and identification of the core set of variables to be used in clinical investigations. Clin Exp Rheumatol 2003;21(Suppl. 29):S47-S56.
21. Appendix. Manual of signs, symptoms, methods and procedures for the assessment of the patient with SSc. Clin Exp Rheumatol 2003; 21(Suppl. 29):S49-S56.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
23. LeRoy EC, Black CM, Fleishmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
24. Clements P, Lachenbrush P, Seibold JR et al. Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
25. Clements PJ, Hurwitz EL, Wong WK et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
26. O'Connor-McCourt MD, Wakefield LM. Latent transforming growth factor β in serum. J Biol Chem 1987;262:14090-9.
27. Pentinen RP, Kobayashi S, Bornstein P. Transforming growth factor β increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA 1988;85:1105-8.
28. Heldin CH, Miyazono K, Dijke P. TGFβ signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390: 465-71.
29. Clark RAF, Nielsen LD, McPherson JM. Collagen matrices express unstimulated and TGFβ - stimulated fibroblast synthesis of collagen. J Cell Biol 1987;105:212A.
30. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGFβ receptors by scleroderma fibroblasts: Evidence for contribution of autocrine TGFβ signalling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
31. Ihn H, Yamane K, Kubo M, Takaki K. Blockade of endogenous transforming growth factor beta signalling prevents up-regulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2002;44:474-80.
32. Miyazono K. TGFβ receptors and signal transduction. Int J Hematol 1997;65:97-104.
33. Kissin EY, Lemaire R, Korn JH, Lafyatis R. Transforming growth factor β induces fibroblast fibrillin-1 matrix. Arthritis Rheum 2002;46:3000-9.
34. Isogai Z, Ono RN, Ushiro S et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003;278:2750-7.
35. Vuorio T, Kahari VM, Black C, Vuorio E. Expression of osteonectin, decorin, and transforming growth factor-β in fibroblasts cultured from patients with systemic sclerosis and morphoea. J Rheumatol 1991;18:247-51.
36. Hasegawa M, Sato S, Takehara K. Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Arch Dermatol Res 2004;296:89-93.
37. Grainger DJ, Kemp PR, Metcalfe JC et al. The serum concentration of active transforming growth factor β is severely depressed in advanced atherosclerosis. Nat Med 1995;1:74-9.
38. Stefoni S, Cianciolo G, Donati G et al. Low TGFβ1 serum levels are a risk factor for atherosclerotic disease in ESRD patients. Kidney Int 2002;61:324-35.